Terms: = Head and neck cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
466 results:
1. An investigative meta-analysis on the effectiveness and safety of integrating VEGF/vegfr inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC.
Wang H; Hu L; Zhang F; Fang M; Xu J; Li M; Chen Z
Oral Oncol; 2024 Jun; 153():106814. PubMed ID: 38714115
[TBL] [Abstract] [Full Text] [Related]
2. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract] [Full Text] [Related]
3. Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett's Neoplasia.
van Munster SN; Verheij EPD; Ozdemir Ö; Toes-Zoutendijk E; Lansdorp-Vogelaar I; Nieuwenhuis EA; Cotton CC; Weusten BLAM; Alvarez Herrero L; Alkhalaf A; Schenk BE; Schoon EJ; Curvers WL; Koch AD; de Jonge PF; Tang TJ; Nagengast WB; Westerhof J; Houben MHMG; Shaheen NJ; Bergman JJGHM; Pouw RE
Gastroenterology; 2024 Jun; 166(6):1058-1068. PubMed ID: 38447738
[TBL] [Abstract] [Full Text] [Related]
4. Expression of PTGS2 along with genes regulating VEGF signalling pathway and association with high-risk factors in locally advanced oral squamous cell carcinoma.
Kamal MV; Damerla RR; Parida P; Rao M; Belle VS; Dikhit PS; Palod A; Gireesh R; Kumar NA
Cancer Med; 2024 Feb; 13(3):e6986. PubMed ID: 38426619
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
[TBL] [Abstract] [Full Text] [Related]
6. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract] [Full Text] [Related]
7. Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2.
Yang X; Li W; Han X; Wang J; Dai J; Ye X; Meng M
Sci Rep; 2024 Jan; 14(1):879. PubMed ID: 38195651
[TBL] [Abstract] [Full Text] [Related]
8. Integration of scRNA and bulk RNA-sequence to construct the 5-gene molecular prognostic model based on the heterogeneity of thyroid carcinoma endothelial cell.
Ni Z; Cong S; Li H; Liu J; Zhang Q; Wei C; Pan G; He H; Liu W; Mao A
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):255-269. PubMed ID: 38186223
[TBL] [Abstract] [Full Text] [Related]
9. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
[TBL] [Abstract] [Full Text] [Related]
10. Development and validation of an individualized angiogenesis and tumor-infiltrating lymphocytes prognostic signature in nasopharyngeal carcinoma.
Zhang R; Liao X; Zhang B; Huang X; Qin G; Kong X; Xie Y; Mo Y; Dai J; Gan C; Luo Z; Lu J; Jiang W
Pathol Res Pract; 2024 Jan; 253():154936. PubMed ID: 38006840
[TBL] [Abstract] [Full Text] [Related]
11. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid cancer Treated With vegfr TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
12. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Hanna GJ; Ahn MJ; Muzaffar J; Keam B; Bowles DW; Wong DJ; Ho AL; Kim SB; Worden F; Yun T; Meng X; Van Tornout JM; Conlan MG; Kang H
Clin Cancer Res; 2023 Nov; 29(22):4555-4563. PubMed ID: 37643133
[TBL] [Abstract] [Full Text] [Related]
13. Inhibition of vegfr2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma.
Onda M; Ota A; Ito K; Ono T; Karnan S; Kato M; Kondo S; Furuhashi A; Hayashi T; Hosokawa Y; Kazaoka Y
Cancer Med; 2023 Aug; 12(15):16416-16430. PubMed ID: 37341071
[TBL] [Abstract] [Full Text] [Related]
14. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ; Liao CY; Karrison T; de Souza JA; Worden FP; Libao B; Krzyzanowska MK; Hayes DN; Winquist E; Saloura V; Prescott K; Villaflor VM; Seiwert TY; Schechter RB; Stadler WM; Cohen EEW; Vokes EE
Ann Oncol; 2023 Aug; 34(8):714-722. PubMed ID: 37182801
[TBL] [Abstract] [Full Text] [Related]
15. Candidate Angiogenesis-Related Biomarkers in Patients with Laryngeal Carcinoma (AngLaC): A Prospective Cohort Study.
Pamuk AE; Gedik ME; Sutay Suslu N; Gunaydin G
Otolaryngol Head Neck Surg; 2023 Jun; 168(6):1433-1442. PubMed ID: 36939422
[TBL] [Abstract] [Full Text] [Related]
16. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
[TBL] [Abstract] [Full Text] [Related]
17. Perioperative Tailored Treatments for Gastric cancer: Times Are Changing.
Lavacchi D; Fancelli S; Buttitta E; Vannini G; Guidolin A; Winchler C; Caliman E; Vannini A; Giommoni E; Brugia M; Cianchi F; Pillozzi S; Roviello G; Antonuzzo L
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902306
[TBL] [Abstract] [Full Text] [Related]
18. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
[TBL] [Abstract] [Full Text] [Related]
19. Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid cancer.
Ly NS; Li J; Faggioni R; Roskos LK; Brose MS
Clin Pharmacokinet; 2023 Apr; 62(4):587-598. PubMed ID: 36869986
[TBL] [Abstract] [Full Text] [Related]
20. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
[Next]
